Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (the "Company") on November 13, 2019. The report details the entry into a Material Definitive Agreement regarding a registered public offering of securities.
Key Financial Metrics
- Gross Proceeds: Approximately $1.8 million (before deducting offering expenses).
- Securities Issued: Pre-funded warrants to purchase up to 2,222,223 shares of Common Stock.
- Offering Price: $0.80 per pre-funded warrant.
- Exercise Price: $0.01 per share for the underlying Common Stock.
- Debt and Liquidity: The filing text does not provide specific values for total debt, cash flow, or liquidity ratios outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement on November 13, 2019. The Company agreed to issue pre-funded warrants to investors who would otherwise exceed a 9.99% beneficial ownership threshold if they purchased common stock directly. This structure ensures compliance with Nasdaq Listing Rule 5635(d) regarding minimum price requirements.
Outlook, Risks, and Unusual Items
- Offering Structure: The pre-funded warrants are exercisable immediately and may be exercised at any time until fully exercised.
- Ownership Limits: The number of shares exercisable is limited to ensure no investor beneficially owns more than 9.99% of the outstanding Common Stock immediately following exercise.
- Registration: The offering is conducted pursuant to a Registration Statement on Form S-3 (333-220236), declared effective on September 14, 2017.
- Legal Opinion: The validity of the warrants is supported by a legal opinion from Reed Smith LLP.
Investor Verification Checklist
- Verify the final net proceeds after deducting offering expenses.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific investor rights and covenants.
- Check the prospectus supplement intended for filing on or about November 13, 2019, for additional terms.